Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Rome Therapeutics is a biotechnology company focused on pioneering a new class of medicines by targeting the vast, under-explored region of the human genome known as the repeatome. The company aims to translate insights from this "dark genome" into transformative therapies for serious diseases, initially focusing on cancer and autoimmune disorders. By understanding how repetitive sequences of DNA impact cellular function and disease, Rome is developing novel drugs against previously undruggable targets.
The Cambridge headquarters serves as the central hub for Rome's research and development operations, strategic planning, and corporate administration. It houses state-of-the-art laboratories and office spaces.
Located in Technology Square, a renowned center for innovation and life sciences, providing access to a rich ecosystem of academic institutions, research organizations, and other biotech companies. Facilities likely include advanced molecular biology, biochemistry, and cell biology labs.
A dynamic, science-driven, and collaborative environment, typical of innovative biotech startups, with an emphasis on cutting-edge research, teamwork, and a mission-oriented approach to drug discovery.
The Cambridge location places Rome Therapeutics at the epicenter of biotechnological innovation, facilitating collaborations, talent acquisition, and access to leading research and venture capital.
While headquartered in the US, Rome Therapeutics operates within the global biopharmaceutical ecosystem. Its research into the repeatome has global implications for treating diseases like cancer and autoimmune disorders. The company may engage in international collaborations with academic institutions, research partners, and clinical trials across different regions. Its investor base also includes international entities, reflecting a global interest in its innovative science.
400 Technology Square, 9th Floor
Cambridge
MA
USA
Address: N/A
Focus on centralized operations at the main R&D and corporate hub to foster close collaboration and streamline development efforts.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Rome Therapeutics' leadership includes:
Rome Therapeutics has been backed by several prominent investors over the years, including:
In the past 12 months (May 2023 - May 2024), Rome Therapeutics has strengthened its leadership team with a key C-suite appointment in human resources. No major executive departures have been publicly announced during this period.
Discover the tools Rome Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Rome Therapeutics appears to utilize a common corporate email format. Based on publicly available information, such as contact details in press releases or conference materials, and standard industry practices, the most likely format is the first initial of the first name followed by the full last name.
[first_initial][last]@rometherapeutics.com
Format
rkapeller@rometherapeutics.com
Example
85%
Success rate
Business Wire • May 9, 2023
ROME Therapeutics announced the appointment of Karen Zaderej as Chief People Officer. Ms. Zaderej brings extensive experience in human resources and talent management within the biopharmaceutical industry and will lead ROME's efforts to attract, develop, and retain top talent....more
PR Newswire • February 14, 2023
Rome Therapeutics announced the completion of a $72 million extension to its Series B financing, bringing the total Series B round to $149 million. The funding will support the advancement of its lead program, an LTR-retrotransposon inhibitor for autoimmune disease, into clinical development and further progress its oncology pipeline....more
Business Wire • January 5, 2023
ROME Therapeutics announced the appointment of Menachem Fromer, Ph.D., as Chief Data Science Officer. Dr. Fromer will lead the company's data science strategy and computational platform to further unlock the therapeutic potential of the repeatome....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Rome Therapeutics, are just a search away.